Significance Statement
======================

Providing algorithm-guided antidepressive treatments is considered an important strategy to optimize treatment delivery and avoid or overcome treatment-resistant courses of major depressive disorder (MDD), still a major challenge in the treatment of depression. The clinical benefit of algorithms in the treatment of inpatients with MDD had not been investigated in a large-scale, randomized, controlled trial before. The aim of the German Algorithm Project therefore was to evaluate the effects of treatment algorithms in the care of inpatients with MDD. Results show that a stepwise treatment regimen with critical decision points at the end of each treatment step based on standardized measurements of response and an algorithm-guided decision-making process increases the chance of achieving remission and optimizes prescription behaviors for antidepressants.

Introduction {#s1}
============

About 30% to 40% of patients with major depressive disorder (MDD) do not respond to their first medication trial. More than one-half of these nonresponders do not respond to a second treatment step ([@CIT0015]; [@CIT0003]; [@CIT0028]). Even among those who respond, up to 50% maintain residual symptoms ([@CIT0017]; [@CIT0018]; [@CIT0007]), which increases the risk of relapse and chronicity ([@CIT0025]; [@CIT0007], [@CIT0008]; [@CIT0010]).

Treatment algorithms are regarded as key instruments to optimize treatment delivery and outcomes. These explicit treatment protocols aim at a predefined treatment goal (e.g., remission or response). The major procedural elements of treatment algorithms are strategies (which treatments to use), tactics (how to implement the treatments), treatment steps (in what order to implement the different treatments), standardized evaluation instruments, and critical decision points (CDPs). At CDPs, treatment outcome is assessed and a standardized medical decision is derived based on preset "if-then-rules" ([@CIT0027]; [@CIT0002]). A review of 24 depression disease management programs including treatment algorithms revealed a significant improvement in depressive symptoms, significantly greater patient satisfaction, and better compliance with treatment but also increased healthcare costs ([@CIT0005]) compared with treatment as usual (TAU). However, a large-scale multicenter study to evaluate an algorithm-guided treatment of depressed inpatients has not yet been performed.

The multi-phase German Algorithm Project (GAP) aims to evaluate the efficacy, acceptability, and impact on treatment quality of algorithm-guided depression treatment ([@CIT0002]). An open observational 2-year single-center pilot study (GAP1) suggested reasonable clinical effectiveness and feasibility of a standardized stepwise drug treatment regimen in depressed inpatients ([@CIT0001]). GAP2, a single-center randomized trial, found algorithm-guided treatment was associated with significantly higher remission rates and greater treatment quality than TAU ([@CIT0006]).

The GAP3 study presented here is a multicenter trial conducted within the German Research Network on Depression that included 6 academic and 4 nonacademic psychiatric hospitals. GAP3 compared 2 different treatment assistance approaches: the standardized stepwise drug treatment algorithm (ALGO) and a computerized decision and expert system (CDES) that recommends medications based on the patient's individual medication history and regular reminders to change or maintain the treatment based on the current response pattern. Both approaches, which will be described in detail in the Methods section (study design), were compared to TAU in terms of treatment efficacy, treatment quality, tolerability, and acceptance of treatment.

We hypothesized that algorithm-guided treatment results in superior outcomes compared with TAU. In addition, we aimed to compare outcomes of the highly schematic ALGO and the partially individualized CDES. Within the 3 ALGO groups, 3 arms compared different second-step strategies (lithium augmentation; ALGO LA), dose escalation of the initial substance (ALGO DE), and switch to another antidepressant (ALGO SW) in nonresponders to an initial medium-dose antidepressant monotherapy.

Methods {#s2}
=======

This randomized controlled parallel-designed clinical multicenter GAP3 trial, conducted between 2000 and 2005, was part of a naturalistic study ([@CIT0030]) that described the outcomes of all depressed inpatients from admission to discharge with the primary diagnosis of a major depressive episode according to ICD-10.

Participants {#s3}
------------

Adult inpatients (aged 18--70 years) with a current major depressive episode (unipolar, with or without psychotic symptoms, but not with bipolar depression) and a 21-item Hamilton Depression Rating Scale (HAMD-21) ([@CIT0020]; [@CIT0036]) score of ≧15 were study eligible. Exclusion criteria were: pregnancy or breastfeeding, preexisting psychotropic medication treatment that could not be discontinued, and specific medical conditions that presented a limitation for any possible study treatment (e.g., renal insufficiency as a limitation for lithium). All patients admitted to each participating center were systematically assessed for eligibility. Each local ethical committee approved and monitored the study. All study participants provided written informed consent.

Study Design {#s4}
------------

[Figure 1](#F1){ref-type="fig"} summarizes the study design. Upon enrollment, patients were equally randomized into 5 treatment groups. Within the 3 ALGO groups, all participants began with any 1 of 4 different antidepressants chosen to represent common pharmacological classes: (selective-serotonin-reuptake-inhibitor) sertraline; (serotonin-noradrenalin-reuptake-inhibitor) venlafaxine; (selective-nor-adrenaline-reuptake-inhibitor) reboxetine; (tricyclic antidepressant) amitriptyline. The second steps represent 3 different common next step strategies (ALGO LA, ALDO DE, or ALGO SW) that could be taken when nonresponse to the first step (4-week medium dose antidepressant monotherapy) occurred. For this report, we label each pathway by the second step itself. The subsequent steps in ALGO also differed as depicted in [Figure 1](#F1){ref-type="fig"}. ALGO mandated further strategies based on prior responses to each step. For ALGO LA, serum levels were assessed weekly (target dose 0.6--0.8 mmol/L) ([@CIT0007]). As part of the ALGO procedure, the HAMD-21 score difference between the beginning and the end of each 4-week step was used to ascribe remission, partial response, or nonresponse as the outcome. Remission was declared with a HAMD-21 ≤9. Remission was to be confirmed in a retest after 2 weeks. If recurrence was observed, the patient either received a 2-week prolongation of the specific treatment step (if HAMD-21 = 10--14) or directly moved to the next step (if HAMD-21 was ≥15).

![Overview of the study design. ALGO, standardized stepwise drug treatment algorithm; ALGO DE, ALGO pathway with dose escalation; ALGO LA, ALGO pathway with lithium augmentation; ALGO SW, ALGO pathway with antidepressant switch; CDES, computerized documentation and expert system; ECT, electroconvulsive therapy; MAO-inhibitor, monoamine oxidase inhibitor; TAU, treatment as usual. The indicated doses refer to doses per day.](pyx04301){#F1}

If partial response occurred (defined as a score reduction of \>8 or \>30% without achieving remission), a 2-week prolongation of the current treatment step was allowed (only once per step). Nonresponse was defined as not meeting remission or partial response criteria. These patients moved to the next treatment step.

CDES used individual patients' information, prior treatment history, risk factors, and responses to the current treatment with a probability matrix to generate suggestions based on a clinical data pool derived from treatment courses of 650 patients with MDD ([@CIT0022]; [@CIT0014]). The software calculated the probability of an individual patient's response every 2 weeks based on the HAMD-21 score. If response was determined to be likely, the system recommended maintaining the strategy. In cases of unlikely responses, the software recommended changing the current strategy but in a more general way (e.g., "consider augmentation or switch to another compound"). In addition, CDES provided an overview of past treatments and listed previous treatments associated with response or nonresponse or side effects in each patient (for additional information please see Appendix 1). The fifth group received TAU.

Measures {#s5}
--------

A systematic interview ([@CIT0011]) captured baseline clinical and socio-demographic features of the sample. Clinical diagnoses were confirmed with the Structured Clinical Interview for DSM-IV ([@CIT0037]). The Structured Clinical Interview-II assessed comorbid personality disorders ([@CIT0037]).

In all 5 groups, treatment outcome was assessed every 2 weeks (±3 days) by nonmasked research staff who were uninvolved in treatment. The primary outcome based on the HAMD-21 was time to remission (HAMD-21 ≤9).

Secondary outcomes included dropout rates and treatment process parameters for each group (e.g., number of strategy changes, ascribed when a new medication was added or discontinued; total number of psychotropic medications, number of different pharmacological drug classes).

Medication doses were calculated as defined drug doses, the assumed average maintenance dose per day for a medication used for its main indication in adults ([@CIT0035]). We used the recommendations in the Antidepressant Treatment History Form to define adequate doses of antidepressants ([@CIT0029]) based on the minimal dosage at which randomized controlled trials have shown the agent to be effective in major depression. Dropout reasons were withdrawal of consent, discharge or transfer to another hospital (patient's or doctor's choice) before remission or final rating, protocol violations, side effects, or suicide (supplementary Table 1). Patients from TAU were rated as dropouts in case of withdrawal of consent, premature discharge, or suicide.

Concomitant Treatments {#s6}
----------------------

Modest concomitant medication restrictions were placed on patients in ALGO. Lorazepam and non-benzodiazepine hypnotics (zopiclone and zolpidem) were permitted for agitation, anxiety, or sleeping problems. In psychotic depression, risperidone (up to 4 mg/d) or olanzapine (up to 15 mg/d) were allowed as co-medication.

Randomization and Masking {#s7}
-------------------------

Randomization was performed in blocks of 10, separately for each study site, and random figures were generated using [www.randomizer.org](http://www.randomizer.org). Study staff and patients were masked to the randomization code until inclusion assessment was finished. Thereafter, patients, physicians, and outcome assessors were not blinded to the treatment allocation.

Statistical Analysis {#s8}
--------------------

The sample size estimate of 450 participants was based on the primary outcome variable: time to remission. Assumptions were a variance of 4 weeks and a mean difference of 2 weeks between groups was used a priori to define clinical relevance. This is equivalent to an effect size of d=0.50, and power would be 0.80. To account for dropouts, 90 patients had to be enrolled per study group.

SPSS (Statistical Package for Social Science) version 18.0 was used for statistical operations. Calculations were performed with SAS version 6.12 for Windows NT and UnifyPow. Differences in baseline or treatment characteristics between the groups (ALGO groups, CDES, and TAU) were assessed using a chi-squared test or logistic regression for categorical variables and an ANOVA for continuous variables. With an alpha error of 5%, statistical significance for all analyses was assumed with *P* \< .05 (2-tailed). Survival analysis was conducted to be able to use all patient data including right-censored cases due to dropout events. It was assumed that treatment response did not differ between patients remaining in the study until remission and dropout. Median survival times were calculated using Kaplan-Meier statistics. Differences in time to remission were analyzed using Cox Regression Modeling. Model comparison was based on the likelihood ratio test (LRS). Of primary interest was an overall difference between groups. This was evaluated using the likelihood ratio test. All other comparisons were performed exploratively and thus no type I error adjustment was performed.

Results {#s9}
=======

Of 593 patients who entered the naturalistic study ([@CIT0030]) between 2000 and 2005, 475 (80.1%) enrolled in GAP3 at 10 sites (see Acknowledgments). Of these 475 patients, 429 were eligible for further analysis ([Figure 2](#F2){ref-type="fig"}). [Table 1](#T1){ref-type="table"} shows the baseline characteristics of the study sample.

![Overview of remission and dropouts in the study groups and throughout the ALGO pathways. AD mono, antidepressant monotherapy; ALGO, standardized stepwise drug treatment algorithm; ALGO DE, ALGO pathway with dose escalation; ALGO LA, ALGO pathway with lithium augmentation; ALGO SW, ALGO pathway with antidepressant switch; CDES, computerized documentation and expert system; GAP3, German Algorithm Project phase 3; MAOI, monoamine oxidase inhibitor; T3, trijodthyronine; TAU, treatment as usual.](pyx04302){#F2}

###### 

Baseline Characteristics of Study Sample

  -------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                         ALGO LA     ALGO DE     ALGO SW     CDES          TAU           Statistic       *P*
  ---------------------------------------------------------------------- ----------- ----------- ----------- ------------- ------------- --------------- ------
  Sample size                                                            86          91          89          79            84                            

  Female (%)\                                                            65.9        62.6        62.9        74.7          51.2          Chi^2^=9.978    .041
  n=428                                                                                                                                                  

  Age (years: M, sd)\                                                    45.6±11.1   44.3±13.3   42.2±13.4   43.6 ± 12.5   45.1 ± 11.7   F=1.012         .401
  n=429                                                                                                                                                  

  Married / partnership (%)\                                             45.0        34.9        44.6        38.9          38.2          Chi^2^=2.619    .623
  n=397                                                                                                                                                  

  Number of children (M, sd)\                                            1.3±1.1     1.1±1.3     1.1±1.1     1.0±1.0       1.1±1.1       F=0.724         .576
  n=356\                                                                                                                                                 

  Employed (full- or part-time) (%)\                                     45.1        32.1        55.7        33.8          36.1          Chi^2^=12.526   .014
  n=385                                                                                                                                                  

  High school diploma (%)\                                               26.6        31.0        36.6        27.8          25            Chi^2^=3.187    .527
  n=389                                                                                                                                                  

  any school qualification (%)\                                          92.4        97.6        96.3        90.3          98.6          Chi^2^=8.169    .086
  n=389                                                                                                                                                  

  Vocational qualification (%)\                                          71.3        75.3        81.0        81.4          86.5          Chi^2^=6.507    .164
  n=388                                                                                                                                                  

  Depressive Episode, single (%)\                                        53.6        40.0        59.8        37.7          42.7          Chi^2^=12.232   .016
  n=420                                                                                                                                                  

  Psychotic symptoms (%)\                                                10.7        5.6         8.0         5.2           3.7           Chi^2^=4.117    .390
  n=420                                                                                                                                                  

  Depression severity at baseline (HAMD-21 score; M, sd)\                25.9±6.5    25.4±5.3    25.4±5.8    25.6±6.0      27.4±6.3      F=1.668         .156
  n=429                                                                                                                                                  

  Duration of current episode (weeks; M, SD)\                            20.8±31.3   13.6±15.4   15.9±14.8   29.5±73.7     18.6±24.7     F=1.280         .278
  n=246                                                                                                                                                  

  Duration since illness onset (years; M, SD)\                           5.8±8.5     8.8±10.7    5.5±9.4     10.4±13.0     8.3±8.2       F=2.229         .066
  n=262                                                                                                                                                  

  Total number depressive episodes, including current episode (M, SD)\   2.3±2.1     2.7±2.9     1.8±1.4     2.4±1.7       2.8±2.4       F=1.660         .160
  n=251                                                                                                                                                  

  Comorbidity                                                                                                                                            

   Psychiatric (%) n=420                                                 27.1        24.7        20.7        22.1          24.4          Chi^2^=1.145    .887

   Personality disorder (%) n=429                                        5.8         12.1        10.1        8.9           8.3           Chi^2^=2.282    .684
  -------------------------------------------------------------------------------------------------------------------------------------------------------------

ALGO: standardized stepwise drug treatment algorithm; ALGO LA: ALGO pathway with lithium augmentation; ALGO DE: ALGO pathway with dose escalation; ALGO SW: ALGO pathway with antidepressant switch; HAMD: Hamilton Rating Scale for Depression; BDI: Beck Depression Inventory; CDES: computerized documentation and expert system, TAU: treatment as usual.

Time to Remission {#s10}
-----------------

Cox regression survival analysis showed a significant difference in median time to remission between groups (42 \[95% CI 30.95--53.05\] days for ALGO LA, 37 \[Cl 28.36--45.64\] days for ALGO DE, 40 \[95% Cl 29.21--50.79\] days for ALGO SW, 45 \[95% Cl 32.74--57.25\] days for CDES vs 45 \[95% Cl 32.09--57.91\] days for TAU, likelihood ratio test=11.078, *P*=.026). Compared with TAU, subsequent Cox regression analysis showed that the probability for remission was significantly higher for ALGO DE (HR=1.67 \[95%CI 1.11--2.52\] Wald test=6.03, *P*=.014) and for ALGO SW (HR=1.64 \[95%CI 1.10--2.48\] Wald test=5.60, *P*=.018), but narrowly missed statistical significance for ALGO LA (HR=1.49 \[95%CI 0.99--2.25\] Wald test=3.69, *P*=.055), while there was no difference for time to remission between CDES and TAU (HR=1.06 \[95% CI 0.68--1.63\], Wald test=0.06, *P*=.811) (HR=1.06 \[95% CI 0.68--1.63\], Wald test=0.06, *P*=.811). Compared with CDES, probability for remission was significantly higher for ALGO DE (HR=1.59 \[95% CI 1.04--2.41\] Wald test=4.64, *P*=.031), for ALGO SW (HR=1.56 \[95%CI 1.03--2.37\] Wald=4.30, *P*=.038), but not for ALGO LA (HR=1.42 \[95%CI 0.93--2.15\] Wald test=2.66, *P*=.103) ([Figure 3](#F3){ref-type="fig"}).

![Time to remission for standardized stepwise drug treatment algorithm (ALGO) pathway with lithium augmentation (ALGO LA), ALGO pathway with dose escalation (ALGO DE), ALGO pathway with antidepressant switch (ALGO SW), computerized documentation and expert system (CDES), and treatment as usual (TAU).](pyx04303){#F3}

Remission and Dropout Analysis {#s11}
------------------------------

Of 429 patients, 235 (54.8%) achieved remission and 276 (64.3%) achieved response during the study (reduction of HAMD-21 score ≥50%). Remission or response rates during the study and time in hospital were not different between the 5 groups ([Table 2](#T2){ref-type="table"}).

###### 

Remission and Response^*a*^

                               ALGO LA       ALGO DE       ALGO AS       CDES          TAU           statistic        *P*
  ---------------------------- ------------- ------------- ------------- ------------- ------------- ---------------- ------
  Remission (n, %)             51 (59.3)     52 (57.1)     51 (57.3)     39 (49.4)     42 (50)       chi^2^ = 2.853   .583
  Response (n, %)              54 (62.8)     57 (62.6)     59 (66.3)     45 (57)       61 (72.6)     chi^2^ = 4.736   .315
  Total time in hospital (d)                                                                                          
  Completer (M, SD)            50.5 (28.6)   53.4 (25.3)   55.9 (34.3)   49.3 (26.1)   52.4 (29.7)   F = 0.183        .833
  Total sample (M, SD)         53.6 (37.1)   55.6 (34.1)   55.4 (42.2)   58.6 (45.6)   50.6 (32.5)   F = 0.363        .835

Abbreviaitons: ALGO, standardized stepwise drug treatment algorithm; ALGO DE, ALGO pathway with dose escalation; ALGO LA, ALGO pathway with lithium augmentation; ALGO SW, ALGO pathway with antidepressant switch; CDES, computerized documentation and expert system; TAU, treatment as usual.

^*a*^Remission (HAMD-21≤9), response (reduction of HAMD-21 score ≥50%) during study duration and time in hospital for ALGO.

Overall, 169/429 (39.4%) dropped out of the study protocol for various reasons (see supplementary Table 1). Dropouts were less frequent in TAU (19%) than in each of the 3 ALGO pathways: ALGO LA (40.7%), ALGO DE (42.9%), ALGO SW (42.7%), as well as CDES (50.6%) (chi-square=19.70; *P*=.001).

[Figure 2](#F2){ref-type="fig"} provides an overview of remission and dropout rates per step or per week. Within ALGO, most of the remissions (45.1% of the intention-to-treat \[ITT\] sample, 77.9% of remitted patients) and most of the dropouts (36.1% of ITT sample, 85.7% of dropouts) occurred during the first (antidepressive monotherapy) step. In the second and third steps, another 9.8% and 3%, respectively, of the initial sample achieved remission. In CDES, most of the remissions (64.1% of remitted patients, 31.6% of ITT sample) and of dropouts (57.5% of dropouts, 29.1% of ITT sample) occurred during the first 4 weeks of treatment. In TAU, 50% of final remitters remitted during the first 4 weeks of treatment (25% of ITT sample).

Status at Discharge {#s12}
-------------------

At hospital discharge, HAMD-21 data were available for 318/429 (74.1%) of participants of whom 245/318 (77%) were remitted. A total of 76.6% of patients from the ALGO LA pathway were remitted compared with 89.2% of patients from ALGO DE, 85.5% from ALGO SW, 67.7% from CDES, and 66.2% from TAU (chi-square =15.36, *P*=.004).

Treatment Features {#s13}
------------------

Complete medication data were available for 350 patients. The subgroup analysis of those patients who achieved remission (n=217) showed that patients in ALGO LA and ALGO DE needed fewer different kinds of antidepressants than patients in either CDES or TAU ([Table 3](#T3){ref-type="table"}), even when taking into account time to remission in an ANCOVA.

###### 

Characteristics of Pharmacological Treatment

                                                     ALGO LA         ALGO DE         ALGO AS         CDES            TAU                    
  -------------------------------------------------- --------------- --------------- --------------- --------------- --------------- ------ ------
                                                     M (SD)          M (SD)          M (SD)          M (SD)          M (SD)          F      P
  Number of antidepressants                          1.00 (0.00)     1.00 (0.00)     1.22 (0.42)     1.29 (0.58)     1.29 (0.46)     7.21   .000
  Defined daily doses (DDD) of antidepressants       61.09 (42.03)   69.62 (59.85)   57.94 (36.73)   61.59 (59.06)   80.15 (71.51)   1.16   .329
  Treatment duration with 1st antidepressant (d)     31.22 (18.36)   31.40 (18.72)   27.41 (11.99)   31.26 (19.84)   34.21 (20.85)   0.83   .510
  Number of different pharmacological drug classes   2.54 (1.09)     2.57 (1.14)     2.47 (0.92)     2.76 (1.02)     2.44 (1.18)     0.53   .716
  Number of strategy changes                         1.59 (0.88)     1.68 (1.09)     1.98 (1.55)     1.97 (1.57)     2.20 (1.75)     1.38   .241
  Number of hypnotics                                0.72 (1.07)     0.62 (0.82)     0.59 (0.79)     0.76 (0.65)     0.41 (0.67)     1.07   .372
  Defined daily doses (DDD) of hypnotics             8.31 (17.26)    9.04 (14.92)    16.45 (53.83)   11.11 (18.06)   7.49 (18.36)    0.69   .599
  Treatment duration with hypnotics (d)              7.70 (12.03)    8.96 (14.06)    10.12 (18.74)   11.56 (16.89)   6.95 (14.49)    0.56   .689
  Number of tranquilizer                             0.63 (0.57)     0.60 (0.54)     0.67 (0.47)     0.74 (0.57)     0.56 (0.55)     0.61   .653
  Defined daily doses (DDD) of tranquilizer          4.41 (7.55)     7.98 (15.16)    9.41 (15.89)    6.92 (12.05)    9.64 (19.16)    0.97   .423
  Treatment duration with tranquilizer (d)           7.20 (10.92)    8.91 (14.06)    11.14 (16.13)   9.29 (14.26)    9.32 (14.89)    0.47   .760
  Number of Antipsychotics                           0.28 (0.72)     0.49 (0.83)     0.37 (0.67)     0.35 (0.65)     0.27 (0.67)     0.69   .601
  Defined daily doses (DDD) of antipsychotics        3.20 (10.35)    8.35 (19.05)    5.08 (15.68)    4.12 (11.94)    6.15 (25.42)    0.59   .669
  Treatment duration with antipsychotics (d)         4.46 (11.98)    8.93 (16.42)    4.88 (11.99)    4.53 (11.22)    7.29 (23.03)    0.74   .563

Abbreviations: ALGO, standardized stepwise drug treatment algorithm; ALGO AS, ALGO pathway with antidepressant switch; ALGO DE, ALGO pathway with dose escalation; ALGO LA, ALGO pathway with lithium augmentation; CDES, computerized documentation and expert system; TAU, treatment as usual.

DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults; each new prescription and each discontinuation was considered a strategy change.

Of remitters, (n=217) 46.5% received hypnotics. CDES patients were more likely to be prescribed hypnotics than TAU patients (OR=3.95 \[95 % CI 1.51--10.34\], *P*=.005), but not patients in the ALGO pathways ([Table 3](#T3){ref-type="table"}).

Until remission, 12% of the patients (26/217) were treated with antidepressant doses below the minimal effective dose in at least one of the prescribed antidepressants. The risk of being treated with insufficiently dosed antidepressants was significantly higher in CDES than TAU (OR=6.00 \[95% CI 1.18--30.53\], *P*=.031), whereas patients in the 3 ALGO pathways were at significantly lower risk compared with CDES (ALGO LA (OR=0.15 \[95% CI 0.03--0.75\], *P*=.021), in ALGO DE (OR=0.144 \[95% CI 0.03--0.73\], *P*=.019), and in ALGO SW (OR=0.14 \[95% CI 0.03--0.70\], *P*=.017). There was no significant difference between ALGO groups and TAU.

Discussion {#s14}
==========

Study results indicated that algorithm-guided treatment of depression (ALGO) is generally associated with a shorter time to remission than either an individualized CDES or TAU. Probability of achieving remission was significantly higher for ALGO DE and ALGO SW but narrowly failed statistical significance for ALGO LA. Dropout rates are relatively high in all 3 ALGO pathways and less frequent in TAU. ALGO-treated patients who dropped out of the protocol still maintained a higher probability of leaving the hospital in remission than patients in CDES or TAU, although durations of inpatient treatment did not differ between the groups.

We found more insufficient dosing of antidepressants and prescription of hypnotics in CDES and higher numbers of antidepressants used to achieve remission in TAU and CDES groups than for either ALGO LA or ALGO DE pathways.

These findings are in line with our single site GAP2 project ([@CIT0006]), which demonstrated superior clinical outcomes of a similar standardized step-wise treatment algorithm compared with TAU. In contrast, however, the present study did not find that any of the ALGO pathways were associated with fewer strategy changes or less polypharmacy than TAU to achieve remission.

The efficacy of algorithm-guided depression treatments has been shown in several smaller studies and large-scale multi-site projects in different outpatient settings. The Texas Medication Algorithm Project found a superior overall treatment outcome and fewer side effects for patients being treated with a guided medication treatment algorithm ([@CIT0031]). A more recent Japanese study reported a 10% higher remission rate for algorithm-treated patients following a stepwise treatment procedure compared with TAU ([@CIT0039]). A recent randomized controlled study from China showed that measurement-based care, that is, the use of a symptom-rating scale, together with a dosing schedule showed superior outcomes compared with TAU even if medication and dose ranges did not differ between groups ([@CIT0019]). Controlled studies and open trials in geriatric populations also showed the feasibility and effectiveness of intensive managed care programs ([@CIT0016]; [@CIT0021]; [@CIT0023]; [@CIT0034]; [@CIT0009]; [@CIT0004]). The Sequenced Treatment Alternatives to Relieve Depression study evaluated a measurement-based, stepwise treatment approach in a large outpatient sample with nonpsychotic MDD ([@CIT0003]; [@CIT0028]). However, the study failed to show the superiority of any of the compared escalation strategies (different augmentation, combination, or switch strategies) in nonresponders.

Notably, in this study, only a highly schematized algorithm-guided procedure resulted in superior outcomes but not an individualized software-based treatment assistance. This finding supports a major theory in algorithm research that diligent treatment management with a highly structured measurement-based procedure accounts for the difference in treatment outcomes rather than the application of a particular treatment strategy per se ([@CIT0003]; [@CIT0026]). A more individualized treatment guidance that lacks clear-cut treatment strategies and without explicit "if-then" rules is not different from TAU and, therefore, might not be cost effective. In contrast, we even found a higher rate of insufficiently dosed antidepressants in CDES, which might also explain the lower remission and response rates in this group compared with ALGO ([@CIT0026]). This finding shows that algorithms also bear the risk of decrementing treatment processes.

Our results show a shorter time to remission for ALGO DE and ALGO SW but only a nonsignificant trend for ALGO LA compared with CDES and TAU. We had expected lithium augmentation to prove more effective than dose escalation or switch of antidepressant with regard to the broad basis of evidence in favor of this strategy ([@CIT0012]). However, interpretation of our second step results has to be done with caution due to the low number of patients in this study step and insufficient statistical power.

Future studies need to address the question of the appropriate timing of CDPs and different response categories that result in specific operational consequences in a specific clinical environment (outpatients, inpatients, characteristics of health system). The question of which treatment sequences are preferred for particular subpopulations (e.g., stage of treatment resistance, age, presence of psychiatric and nonpsychiatric comorbidities) needs clarification. Before implementation into clinical practice, algorithm developers must ensure feasibility and clinical efficacy of a treatment algorithm in a particular treatment environment and applicability to patient subgroups, as demonstrated by our CDES results.

Study limitations include: the lack of power in all 3 algorithm-guided treatment steps after step one, primarily due to a high remission rate during antidepressant monotherapy. In addition, the study team, clinical staff, and patients were not masked to treatment assignment, which could have led to a bias in favor of the ALGO groups. However, response assessments were performed by staff that was not involved in the treatment of the patient. A conservative bias results from the fact that the same clinicians who treated ALGO and CDES patients also treated patients in TAU, which is expected to result in "contamination" of TAU with ALGO and CDES treatment procedures, thus reducing outcome differences between the groups. Also, differences in distribution of clinical or sociodemographic variables between the treatment groups (such as gender, type of depression \[single vs recurrent\], duration of the illness, or percentage of psychotic depression) could be of clinical relevance and therefore may weaken the interpretation of our results. As the dropout rate in TAU is lower than ALGO or CDES while 2 of the ALGO groups did better in terms of time to remission, it cannot be ruled out that subjects doing poorly in ALGO or CDES dropped out whereas they stayed in the TAU group. However, as survival analysis regards dropouts as treatment failures such a bias seems unlikely to have influenced the result. Results are applicable only to inpatient populations. Inpatient stays in Germany are longer in average compared with the United States, which might limit generalizability. However, the German healthcare system has a relatively low threshold for hospital admission of depressed patients, so results would seem to be generalizable to the more severely ill depressed patients regardless of treatment venue.

In summary, these results demonstrate that an algorithm-guided treatment procedure that entails the regular measurement of outcomes and mandates next steps results in a higher probability of achieving remission and of leaving the hospital in remission than TAU. ALGO reduces the number of antidepressant compounds needed to achieve remission. In contrast, we showed that algorithms may also bear risks, as seen with CDES with its less clear recommendations, and therefore need to be evaluated before implementing them in clinical practice.
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